RIA Advisory Group LLC Has $433,000 Position in Bristol-Myers Squibb (NYSE:BMY)

RIA Advisory Group LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,436 shares of the biopharmaceutical company’s stock after selling 706 shares during the quarter. RIA Advisory Group LLC’s holdings in Bristol-Myers Squibb were worth $433,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $25,000. True Wealth Design LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $26,000. Milestone Investment Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth approximately $27,000. Coppell Advisory Solutions LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth approximately $28,000. Finally, Blue Bell Private Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded up $0.63 during trading hours on Friday, reaching $48.93. The company had a trading volume of 10,298,874 shares, compared to its average volume of 15,709,695. The stock has a 50-day moving average of $51.25 and a two-hundred day moving average of $51.57. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The firm has a market capitalization of $99.17 billion, a PE ratio of 12.56, a PEG ratio of 1.44 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.82 earnings per share. Analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.90%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.